Beverly Hills-based Henislie, a new joint venture created by BioAccel and Imprimatur Capital, said today that it is in the midst of raising approximately $50M to seed investment in companies in the life science, information technology, telecommunications and clean energy production. The firm said the funding would be in the form of short-term, proof-of-concept financing and investments in startup firms. The firm said the funds will go towards funding startups in Southern California, Arizona, and Texas. BioAccel is a nonprofit startup accelerator focused on technology commercialization, and is based in Phoenix; IMprimatur Capital is headquartered in London, England, and invests in enterprise software, electronics, medical technology, homeland security and wireless/mobile companies.
Top NewsWednesday, October 27, 2010
New Firm Looks To Fund Technology Startups